Skip to Content
  • Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
  • Article
  • Open Access

26 October 2007

Ocena wpływu chemioterapii na czas przeżycia i wybrane objawy wpływające na jakość życia chorych na niedrobnokomórkowego raka płuca w IIIB i IV stopniu zaawansowania

,
,
,
and
Klinika Nowotworów Układowych i Uogólnionych Centrum Onkologii, Oddział w Krakowie, ul. Garncarska 11, 31-115 Kraków, Poland
*
Author to whom correspondence should be addressed.

Abstract

Introduction: The study presents treatment results of 168 patients with non small cell lung cancer in stage IIIB and IV treated since year 2002 to 2006 in Oncological Center in Cracow. Material and methods: Four regimens of chemotherapy: EP (cisplatin, vepesid), MVP (mitomycin C, vinblastin, cisplatin), PN (cisplatin,vinorelbin) and PG (cisplatin, gemcytabin) were used. Results: Average survival time in group treated with MVP regimen was 7.8 months (median 4.3 months), PG 7.1 months (median 7.3 months), EP 10.2 months (median 7.5 months), PN 14.1 months (median 9.8 months). Differences in median survival time were not significant. Average time to progression in group treated with MVP regimen was 3.5 months (median 2.6 months), PG 5.2 months (median 5.8 months): EP 6.6 months (median 5.2 months), PN 6.7 months (median 5.6 months). Improvement in control of symptoms regarding dyspnea, pain and cough was reached in 60%, 38.7% and 60% of patients respectively. There were no significant differences between chemotherapy regimens regarding improvement in symptoms control. Conclusions: Cisplatin + vinorelbin regimen can be recommended as standard method because of the best treatment results.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.